Company intelligence / Profile preview

EnChannel Medical

Guangzhou, Guangdong Province, Chinaenchannel.com ↗

Ownership: Private
Development stage: Preclinical

Overview

EnChannel Medical is developing a holistic cardiac electrophysiology platform for the treatment of atrial fibrillation. Their DePolar® Mapping System and NanoAblate® PFA System are investigational devices currently undergoing clinical registration trials in China and internationally. Early clinical results have been encouraging, as presented at major scientific meetings.

Therapeutic areas: Cardiovascular
Modalities: Pulsed-field ablation (PFA)Full-chamber 5D action-potential mappingMagnetic impedance navigationIntracardiac echocardiography
Industry: Physiological Monitoring

Drug pipeline

2 assets

DePolar

Pre-clinical

Indications: Atrial fibrillation

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on EnChannel Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnChannel Medical.

Explore the full profile